Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Iovance Biotherapeutics, Inc. < Previous 1 2 Next > Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024 October 31, 2024 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Tickers IOVA Iovance Biotherapeutics to Present at Upcoming Conferences September 03, 2024 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Tickers IOVA Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) August 16, 2024 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Tickers IOVA Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024 August 08, 2024 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Tickers IOVA Iovance Biotherapeutics to Host Second Quarter and First Half 2024 Financial Results Conference Call and Webcast on Thursday, August 8, 2024 July 29, 2024 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Tickers IOVA Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) July 19, 2024 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Tickers IOVA Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma June 28, 2024 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Tickers IOVA Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) June 21, 2024 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Tickers IOVA Iovance Biotherapeutics to Present at Upcoming Conferences and Events May 24, 2024 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Tickers IOVA Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting May 23, 2024 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Tickers IOVA Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) May 17, 2024 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Tickers IOVA Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates May 09, 2024 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Tickers IOVA Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024 May 01, 2024 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Tickers IOVA Iovance Biotherapeutics to Present at Upcoming Conferences April 30, 2024 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Tickers IOVA Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting April 24, 2024 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Tickers IOVA Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) April 19, 2024 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Tickers IOVA Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) March 22, 2024 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Tickers IOVA Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer March 04, 2024 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Tickers IOVA Iovance Biotherapeutics to Present at Upcoming Conferences March 01, 2024 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Tickers IOVA Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates February 28, 2024 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Tickers IOVA Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024 February 22, 2024 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Tickers IOVA Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock February 20, 2024 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Tickers IOVA Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) February 16, 2024 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Tickers IOVA Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024 February 16, 2024 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Tickers IOVA Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma February 16, 2024 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Tickers IOVA Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) January 19, 2024 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Tickers IOVA Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer December 27, 2023 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Tickers IOVA Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) December 22, 2023 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Tickers IOVA Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) November 17, 2023 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Tickers IOVA Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates November 07, 2023 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Tickers IOVA < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
